Drug Pricing

  • A picture from chest-up of Bernie Sanders speaking to reporters. The top of the US capitol building is visible behind him.
    Image attribution tooltip
    Anna Moneymaker/Getty Images via Getty Images

    Sanders poised to lead Senate health committee

    The longtime pharma critic is set to become chair of the HELP Committee, a post that holds significant power in directing congressional efforts on healthcare issues.

    By Susan Kelly • Nov. 28, 2022
  • FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar

    Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.

    By Nov. 18, 2022
  • Explore the Trendline
    Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Drug pricing

    Major drug pricing legislation passed Congress in 2022, putting pharmaceutical companies on the defensive and creating a new precedent for the industry.

    By BioPharma Dive staff
  • Xavier Becerra sits on a couch onstage at HLTH.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Dive

    Divided Congress after midterms will allow HHS to execute on policy priorities, Becerra says

    The agency is focused on implementing drug price negotiation in Medicare and surprise billing regulations, according to the secretary.

    By Rebecca Pifer • Nov. 16, 2022
  • Alexis Borisy and Melanie Nallicheri of EQRx, at launch
    Image attribution tooltip
    Courtesy of EQRx

    EQRx redraws ‘radical’ drug pricing plans for first two drugs

    The buzzy startup, which planned to undercut big pharma on price, also dropped plans to seek U.S. approval in lung cancer of an immunotherapy competitor to Keytruda.

    By Nov. 10, 2022
  • Prescriptions drugs on a production line.
    Image attribution tooltip
    zorazhuang via Getty Images

    Pharma earnings outline drug law’s looming impact on sales, development

    While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.

    By Nov. 9, 2022
  • Inflation word on calculator in idea for FED consider interest rate hike
    Image attribution tooltip


    Sponsored by GoodRx

    Inflation Reduction Act: What are the healthcare implications?

    The Inflation Reduction Act helps support American families by lowering prescription drug prices and reducing overall healthcare costs.

    Oct. 31, 2022
  • Sponsored by GoodRx

    Worried about provider consolidation? Learn about GoodRx engagement solutions

    GoodRx has developed strong relationships with both patients and providers over the past decade and is helping pharmaceutical manufacturers address the changes resulting from this trend.

    Oct. 10, 2022
  • A photograph of a box of Amylyx Pharmaceuticals' ALS medicine Relyvrio
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals

    Amylyx sets ALS drug price at $158,000 per year, opening new debate on cost

    The list price is slightly lower than another ALS therapy approved five years ago, but well above what one drug cost watchdog believes to be reasonable, given its purported benefit.

    By Sept. 30, 2022
  • Image attribution tooltip

    Novartis warns of sales hit after federal court turns back patent appeal

    The Swiss company is evaluating “all available options” following the ruling, which could lead to the launch of copycat versions of its MS drug Gilenya.

    By Kristin Jensen • Sept. 21, 2022
  • Image attribution tooltip
    Jeff J Mitchell via Getty Images
    Deep Dive

    Can biosimilars, after years of limited impact, finally make a mark in the US?

    Seven years after the first copycat biologic drug arrived in the U.S., expected cost savings have been modest at best. The next few years will show whether the knockoff drugs can live up to their cut-price promise.

    By Sept. 7, 2022
  • A headshot of Akili CEO Eddie Martucci
    Image attribution tooltip
    Permission granted by Akili Inc.
    Q&A // Emerging biotech

    Akili CEO Martucci sees ‘massive’ need for company’s ADHD video-game treatment

    With enough cash now to last two years, the company, which merged with a SPAC last week, hopes it can change the way children with ADHD are treated.

    By Elise Reuter • Aug. 29, 2022
  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical

    With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy

    On a conference call, BioMarin executives revealed the anticipated price for Roctavian and the company's initial launch plans, which include pay-for-performance deals customized to different markets.

    By Aug. 25, 2022
  • A Bluebird bio employee works at a laboratory.
    Image attribution tooltip
    Permission granted by Bluebird bio

    With $2.8M gene therapy, Bluebird sets new bar for US drug pricing

    Approved for severe beta thalassemia, Zynteglo will test insurers’ willingness to pay for expensive one-time treatments. Its market launch is likely to be watched carefully by other gene therapy developers.

    By Aug. 18, 2022
  • Nancy Pelosi sits at a table to sign the inflation reduction act. She's surrounded by people clapping.
    Image attribution tooltip
    Drew Angerer/Getty Images via Getty Images

    Pharma prepares to continue fight as drug pricing bill passes House

    Analysts have highlighted ways in which drugmakers might seek to sidestep the bill, which President Biden signed into law on Tuesday. 

    By Aug. 15, 2022
  • senator Chuck Schumer pauses under an arch in the United States Senate. Both of his hands are raised and giving a 'thumbs up'
    Image attribution tooltip
    Drew Angerer/Getty Images via Getty Images

    Senate passage of drug pricing bill brings major defeat closer for pharma industry

    The legislation, which would allow Medicare to negotiate prices on up to 60 drugs by 2029, passed on a party-line vote and now goes to the House, where it is expected to pass.

    By Aug. 8, 2022
  • A view of the Capitol Dome from below with an American flag waving in the wind on the left side and blue skies in the background.
    Image attribution tooltip
    iStock via Getty Images

    Pharma CEOs press case against drug price negotiation as bill gains support

    On earnings calls with investors, executives reiterated opposition to legislation advanced by Democrats that would curtail their pricing power in the U.S.

    By Aug. 4, 2022
  • Rendered illustration of human DNA
    Image attribution tooltip
    DKosig via Getty Images

    Roche digs deeper into gene therapy for the eye

    The Swiss drugmaker, which already owns rights to a marketed gene therapy for inherited vision loss, will work with startup Avista Therapeutics to develop better delivery tools for the complex treatments. 

    By July 20, 2022
  • UnitedHealth Group's headquarters building in Minnetonka, Minnesota.
    Image attribution tooltip
    UnitedHealth Group

    UnitedHealth to offer some drugs, including insulin, at no cost share in 2023

    The initiative aims to address inflationary pressures and prevent worse health outcomes down the line, CEO Andrew Witty told investors Friday.

    By Rebecca Pifer • July 15, 2022
  • Image attribution tooltip
    Justin Sullivan via Getty Images

    California to manufacture its own insulin, governor says

    Gov. Gavin Newsom announced a $100 million budget to create a production facility and to develop affordable insulin products, saying the medicines’ high cost “epitomizes market failures.”

    By Susan Kelly • July 11, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Watchdog group cautious on Amylyx’s ALS drug benefits, potential cost

    ICER, an influential nonprofit, suggested in a draft report that Amylyx’s closely watched ALS treatment would not be cost effective if priced on par with a currently available treatment.

    By Updated June 14, 2022
  • Image attribution tooltip

    Roche SMA drug approved in youngest infants, challenging Novartis and Biogen

    Evrysdi, the only oral drug for the neurodegenerative disorder, can now be used to treat babies younger than 2 months who have been identified through newborn screening.

    By May 31, 2022
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen

    Medicare premiums to remain unchanged after Aduhelm price cut spurs review

    HHS Secretary Becerra had sought to cut premiums for seniors sooner, but "legal and operational hurdles" prevented a change mid-year, the department said in a Friday statement.

    By Samantha Liss • May 31, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Drug price hikes moderate as rebates rise, report finds

    List prices for branded medicines rose by nearly 5% last year, according to IQVIA, a figure that fell to 1% after accounting for rebates and discounts.

    By April 21, 2022
  • A calculator and stethoscope rest on a medical bill.
    Image attribution tooltip
    erdikocak via Getty Images

    Hospitals mark up cancer drug prices for private insurance patients, study shows

    Researchers also found U.S. spending on cancer medicines rose from about $39 billion in 2015 to nearly $68 billion in 2019 largely due to manufacturer and hospital market power.

    By Hailey Mensik • April 19, 2022
  • Colonies of bacteria in MacConkey agar
    Image attribution tooltip
    Md Saiful Islam Khan via Getty Images

    UK bid to battle antibiotic resistance yields first subscription-style plan

    Pfizer and Shionogi could receive 10 million pounds, or about $13 million, a year for new antibiotics. International participation might be needed to further spur development, however.

    By April 12, 2022